Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07293403 · ClinicalTrials.gov registry record · Phase 2
Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas
A Phase 2 study, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT07293403 is a Phase 2 study that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 25 participants.
The verdict
NCT07293403, a Phase 2 study, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This phase II trial tests how well duvelisib works as treatment that is given to help keep cancer from coming back after it has disappeared following the initial therapy (maintenance) for patients with peripheral T-cell lymphomas. Duvelisib is in a class of medications called kinase inhibitors. It works by blocking the signals that cause cancer cells to multiply. This helps to stop the spread of cancer cells.
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Bone Marrow Aspiration
- PROCEDURE Bone Marrow Biopsy
- PROCEDURE Computed Tomography
- DRUG Duvelisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2026-06-07 |
| Est. Completion | 2027-11-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07293403
The ClinicalTrials.gov registry entry for NCT07293403 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT07293403 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07293403 about?
NCT07293403 is a clinical study titled "Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas". This phase II trial tests how well duvelisib works as treatment that is given to help keep cancer from coming back after it has disappeared following the initial therapy (maintenance) for patients with peripheral T-cell lymphomas. Duvelisib is in a class of medications called kinase inhibitors. It w...
What is the current status of trial NCT07293403?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2026-06-07. Estimated completion is 2027-11-23.
What interventions are being tested in trial NCT07293403?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Bone Marrow Aspiration (PROCEDURE), Bone Marrow Biopsy (PROCEDURE), Computed Tomography (PROCEDURE), Duvelisib (DRUG).
Who is sponsoring clinical trial NCT07293403?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.